company background image
GOVX logo

GeoVax Labs NasdaqCM:GOVX Stock Report

Last Price

US$0.92

Market Cap

US$12.8m

7D

-10.2%

1Y

-60.3%

Updated

20 Jun, 2025

Data

Company Financials +

GeoVax Labs (GOVX) Stock Overview

A clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms in the United States. More details

GOVX fundamental analysis
Snowflake Score
Valuation2/6
Future Growth5/6
Past Performance0/6
Financial Health3/6
Dividends0/6

GOVX Community Fair Values

Create Narrative

See what 13 others think this stock is worth. Follow their fair value or set your own to get alerts.

US$11.38
FV
91.9% undervalued intrinsic discount
246.26%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
11users have followed this narrative
1 day ago author updated this narrative

GeoVax Labs, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for GeoVax Labs
Historical stock prices
Current Share PriceUS$0.92
52 Week HighUS$11.18
52 Week LowUS$0.73
Beta3.44
1 Month Change-5.63%
3 Month Change-29.41%
1 Year Change-60.31%
3 Year Change-95.11%
5 Year Change-99.34%
Change since IPO-100.00%

Recent News & Updates

author-image

Gedeptin And GEO-MVA Trials Will Shape Vaccine And Cancer Pipelines

Progress in vaccines and strategic partnerships could drive revenue growth from commercialization and global stockpile opportunities.

Recent updates

author-image

Gedeptin And GEO-MVA Trials Will Shape Vaccine And Cancer Pipelines

Progress in vaccines and strategic partnerships could drive revenue growth from commercialization and global stockpile opportunities.

We Think GeoVax Labs (NASDAQ:GOVX) Needs To Drive Business Growth Carefully

Sep 08
We Think GeoVax Labs (NASDAQ:GOVX) Needs To Drive Business Growth Carefully

GeoVax: Possible Vaccine Advancements In 2 Big Indications

Aug 08

GeoVax adds 16% as journal publishes animal study on ebolavirus vaccine

Jul 28

Companies Like GeoVax Labs (NASDAQ:GOVX) Could Be Quite Risky

May 24
Companies Like GeoVax Labs (NASDAQ:GOVX) Could Be Quite Risky

GeoVax: A Legitimate COVID-19 Phase 2 Vaccine Candidate Trading At Only A $25 Million Valuation

Dec 27

We Think GeoVax Labs (NASDAQ:GOVX) Can Afford To Drive Business Growth

Nov 27
We Think GeoVax Labs (NASDAQ:GOVX) Can Afford To Drive Business Growth

GeoVax: Expands Immuno-Oncology Pipeline With Clinical-Stage Program

Oct 03

We Think GeoVax Labs (NASDAQ:GOVX) Can Afford To Drive Business Growth

Aug 14
We Think GeoVax Labs (NASDAQ:GOVX) Can Afford To Drive Business Growth

Shareholder Returns

GOVXUS BiotechsUS Market
7D-10.2%-2.1%0.3%
1Y-60.3%-11.0%10.4%

Return vs Industry: GOVX underperformed the US Biotechs industry which returned -9.9% over the past year.

Return vs Market: GOVX underperformed the US Market which returned 9.9% over the past year.

Price Volatility

Is GOVX's price volatile compared to industry and market?
GOVX volatility
GOVX Average Weekly Movement18.4%
Biotechs Industry Average Movement12.2%
Market Average Movement7.7%
10% most volatile stocks in US Market17.3%
10% least volatile stocks in US Market4.0%

Stable Share Price: GOVX's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: GOVX's weekly volatility has decreased from 28% to 18% over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
198817David Doddwww.geovax.com

GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms in the United States. The company is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. It also developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine.

GeoVax Labs, Inc. Fundamentals Summary

How do GeoVax Labs's earnings and revenue compare to its market cap?
GOVX fundamental statistics
Market capUS$12.80m
Earnings (TTM)-US$24.50m
Revenue (TTM)US$5.59m
2.3x
P/S Ratio
-0.5x
P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
GOVX income statement (TTM)
RevenueUS$5.59m
Cost of RevenueUS$24.64m
Gross Profit-US$19.05m
Other ExpensesUS$5.45m
Earnings-US$24.50m

Last Reported Earnings

Mar 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)-1.77
Gross Margin-340.71%
Net Profit Margin-438.16%
Debt/Equity Ratio0%

How did GOVX perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/06/20 07:57
End of Day Share Price 2025/06/18 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

GeoVax Labs, Inc. is covered by 6 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
James MolloyAlliance Global Partners
null nullCG Capital
Jason KolbertD. Boral Capital LLC.